- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Effect of Grapefruit Juice on the Pharmacokinetics of Adalat CR.
-
- TANAKA Toshiaki
- Bayer Yakuhin, Ltd.
-
- KAWANO Koichi
- Bayer Yakuhin, Ltd.
-
- OKUMURA Kazuhito
- Bayer Yakuhin, Ltd.
-
- ORII Yoshimitsu
- Bayer Yakuhin, Ltd.
-
- TANIGAWA Takahiko
- Bayer Yakuhin, Ltd.
-
- TSUBOI Takashi
- Bayer Yakuhin, Ltd.
-
- HASHIZUME Kensei
- Bayer Yakuhin, Ltd.
-
- YUASA Hideo
- Bayer Yakuhin, Ltd.
-
- KATO Masao
- Bayer Yakuhin, Ltd.
-
- WAKAYAMA Naohiko
- Bayer Yakuhin, Ltd.
-
- HASHIMOTO Kayoko
- Sekino Clinical Pharmacology Clinic
-
- SEKINO Hisakuni
- Sekino Clinical Pharmacology Clinic
-
- MATSUOKA Osamu
- Sekino Clinical Pharmacology Clinic
-
- KAMATA Satoshi
- Sekino Clinical Pharmacology Clinic
-
- NOMURA Masaomi
- Sekino Clinical Pharmacology Clinic
-
- TATEISHI Tomonori
- Clinical Pharmacology, Hirosaki University, School of Medicine
Bibliographic Information
- Other Title
-
- アダラートCR錠の薬物動態に及ぼすグレープフルーツジュースの影響
Search this article
Description
Objectives: We investigated the effect of grapefruit juice (GFJ) on the pharmaco kinetics of the new nifedipine formulation, Adalat CR, which is a once-daily slow release (coat-core) tablet and is formulated to release nifedipine throughout the gastrointestinal tract.<BR>Methods: Single doses of Adalat CR 20 mg and 40 mg were administered with 250 ml of GFJ (Kirin Tropicana® 100%, Kirin Beverage Corp.) or water to eight Japanese healthy young male volunteers using the 4-treatment and 4-period crossover method with a 7-day washout period between treatments. Plasma concentrations of nifedipine and its metabolites (pyridine-form: M-I), and urinary metabolites (M-II and M-III) were measured.<BR>Results: After administration of Adalat CR 20 mg and 40 mg with GFJ, the plasma concentration of nifedipine increased especially at the first peak of Adalat CR, which shows a two-peak profile. Cmax and AUC were significantly increased by 59-80% and 13-23%, respectively and CL was significantly decreased by 12-19%. Cmax ratio of pyridine-form to nifedipine (M I/nifedipine) was significantly decreased. Adalat CR was well tolerated even after administration with GFJ. No clinically relevant changes by GFJ were observed in blood pressure or pulse rate.<BR>Conclusion: Changes in the pharmacokinetics after Adalat CR with GFJ were to a smaller extent compared to other dihydropiridines which are known interact with GFJ, i. e. nisoldipine or felodipine. Increased plasma concentration after administration of Adalat CR with GFJ was within the safe range. A marked interaction of Adalat CR with GFJ was not found. However, since Cmax and AUC increased and CL decreased signifi cantly after the administration of Adalat CR with GFJ, it is recommendable to advise patients to avoid intake of GFJ when Adalat CR is administered.
Journal
-
- Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
-
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 32 (1), 23-33, 2001
The Japanese Society of Clinical Pharmacology and Therapeutics
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205340274688
-
- NII Article ID
- 10011536049
-
- NII Book ID
- AN0025404X
-
- ISSN
- 18828272
- 03881601
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed